A novel blood test to predict postpartum depression before it occurs.
We are commercialising the world’s first early predictive test for postpartum depression using a biomarker-driven and AI-enabled approach.
The first postpartum depression biomarker test and drug discovery database of its kind.
Postpartum depression affects 1 in 5 mothers worldwide, with up to 20% of maternal deaths in the postpartum period attributed to suicide.
We still rely on subjective self-reporting screening questionnaires to assess the risk of a mother developing PPD. Many mothers are not screened at all - leading to a substantial number of mothers being undiagnosed, misdiagnosed and untreated for their depression.
There is currently NO clinical test to screen, predict, diagnose or assess the risk of women developing PPD, leaving a huge unmet gap in maternal health that affects not only the mother but the child and family as a whole.
Ketim Technologies is developing the world’s first protein blood-based objective clinical test for PPD using our proprietary dataset, analytical platform and pipeline. By combining our rich biomarker protein profiles with clinical and health data, our AI/ML-enabled pipeline yields better, more accurate, and objective markers and the discovery of novel therapeutics.
Patient Data
Ketim Technologies partners with maternity hospitals to access birth cohorts and biobanks to curate rich datasets for biomarker discovery.
Biomarker Discovery
Our discovery has unveiled a proprietary novel four-protein biomarker signature that can predict the risk of PPD in a mother with up to 94% sensitivity and specificity (AUC), done at 24 weeks gestation (months before PPD symptoms occur).
Proprietary Database
We are building the world’s first PPD drug discovery pipeline powered by our proprietary database for novel therapeutic discovery using AI/ML enabled tools.
At the forefront of scientific discovery, our biotech company pioneers breakthroughs that redefine possibilities in mental health. By harnessing cutting-edge technology and AI, we are committed to transforming lives and shaping a better future for families and generations to come.
We are starting with perinatal mental health.
The Problem
The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can aid in objectively diagnosing patients and providing individualised treatment recommendations.
Integration of biomarkers, clinical data and full patient history for each individual is compounded - this leads to subjective biases and a high rate of under- and misdiagnoses in perinatal mental health.
Our Solution
Ketim Technologies is focused on changing the paradigm of psychiatric care, by building and easing access to big data and molecular biomarkers through a curated database to impact better and faster treatments, starting with PPD.
What makes our pipeline different?
Powered by deep biomarker profiling and multimodal patient data, our AI uncovers novel targets and matches them to the right patient subgroups for more precise treatments. By seamlessly integrating wet lab validation with advanced AI analytics, we create a continuous feedback loop that refines discoveries and accelerates breakthroughs in psychiatric care.
“Having experienced postnatal depression myself, my lived experience fuels my passion to support other mothers during a time when help can feel out of reach.
My vision is to combine my personal journey with my deep expertise in psychiatric biomarkers to usher in a new era of personalised mental health care”
- Dr Clarissa Yates, CEO of Ketim Technologies